Company Description
Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders.
The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.
It is also developing TVGN 920, a preclinical trial drug for treating cervical cancer; TVGN 960, a preclinical trial drug for treating oropharyngeal cancer; TVGN 601, a preclinical trial drug for treating multiple sclerosis; TVGN 930, a preclinical trial drug for treating Epstein-Barr virus associated lymphomas; and TVGN 116, a product candidate targeted at hepatitis B.
It also offers artificial intelligence platform for drug development. Tevogen Inc. was formerly known as Tevogen Bio Holdings Inc. and changed its name to Tevogen Inc. in July 2026.
The company was incorporated in 2020 and is headquartered in Warren, New Jersey.
| Country | United States |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Ryan Saadi |
Contact Details
Address: 15 Independence Boulevard, Suite #210 Warren, New Jersey 07059 United States | |
| Phone | 877 838 6436 |
| Website | tevogen.com |
Stock Details
| Ticker Symbol | TVGN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1860871 |
| CUSIP Number | 88165K200 |
| ISIN Number | US88165K2006 |
| Employer ID | 98-1597194 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Olivia Dunlea | Chief of Staff to Chief Executive Officer |
| Dr. Ryan H. Saadi M.D., M.P.H. | Co-Founder, Chief Executive Officer and Chairperson |
| Kirti Desai CPA | Chief Financial Officer |
| Tapan V. Shah | Head of Investor Relations and Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 30, 2026 | 8-K | Current Report |
| Sep 16, 2026 | SCHEDULE 13D/A | Filing |
| Sep 16, 2026 | SCHEDULE 13D/A | Filing |
| Sep 16, 2026 | 8-K | Current Report |
| Sep 10, 2026 | 8-K | Current Report |
| Aug 26, 2026 | 8-K | Current Report |
| Aug 24, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 3, 2026 | DEF 14A | Other definitive proxy statements |
| Jul 30, 2026 | 8-K | Current Report |